Literature DB >> 1255754

Antigenic changes of L5178Y lymphoma after treatment with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide in vivo.

A Nicolin, F Spreafico, E Bonmassar, A Goldin.   

Abstract

Immunologic alteration of the L5178Y lymphoma was obtained in vivo after treatment with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DIC). A single dose of 1,3-bis(2-chlorethyl)-1-nitrosourea (BCNU) "CURED" MICE CHALLENGED WITH L5178Y cells that had been treated with DIC (L5178Y/DIC) for four transplant generations; BCNU did not cure mice bearing the parent tumor. The L5178Y/DIC, treated in vivo for five transplant generations, id not grow in syngeneic mice. L5178Y/OIC cell growth and incidences of death were similar to those of parent cells when inoculated into heavily immunosuppressed mice. Adoptive transfer of lymphocytes from spleens of mice sensitized to the drug-altered tumor specifically protected immunosuppressed mice bearing the L5178Y/DIC tumor. Little protection was afforded by lymphocytes immune to the parent L5178Y tumor, whereas nonimmune lymphocytes or lymphocytes immune against unrelated tumors were completely ineffective. Anti-L5178Y/DIC lymphocytes did not cure mice challenged with the parent L5178Y tumor. Irradiated (400 R) mice previously sensitized to L5178Y/DIC cells rejected 10(2)-10(7) inocula of L5178Y/DIC cells and died when the parent L5178Y was used for challenge. It was concluded that antigeni( alterations of L5178Y cells occurred in (BALB/ctcr X DBA/2Cr)F1 mice after treatment with DIC in vivo.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1255754     DOI: 10.1093/jnci/56.1.89

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  10 in total

1.  Adoptive immunity in mice challenged with L1210/DTIC clones.

Authors:  G Canti; L Ricci; O Marelli; P Franco; A Nicolin
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 2.  Chemical xenogenization of experimental tumors.

Authors:  P Puccetti; L Romani; M C Fioretti
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 3.  Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer.

Authors:  Tianqian Zhang; Dorothee Herlyn
Journal:  Cancer Immunol Immunother       Date:  2008-10-17       Impact factor: 6.968

4.  Cell-mediated immunity to chemically xenogenized tumors. I. Inhibition by specific antisera and H-2 association of the novel antigens.

Authors:  L Romani; U Grohmann; F Fazioli; P Puccetti; M G Mage; M C Fioretti
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

5.  Effects of prolonged treatment with decarbazine on tumor metastatic potential in mice bearing Lewis lung carcinoma.

Authors:  S Zorzet; L Perissin; V Rapozzi; S Pacor; T Giraldi
Journal:  Clin Exp Metastasis       Date:  1995-03       Impact factor: 5.150

6.  A murine plasmacytoma MOPC 104E resistant to cyclophosphamide is resistant to immunotherapy.

Authors:  K Satoh; N Kan; T Okino; M Nakanishi; K Mise; Y Teramura; S Yamasaki; K Ohgaki; T Tobe
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Two antiemetic regimens do not impair chemical xenogenization induced in vivo by 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide.

Authors:  P Ballerini; A Franchi; P Fuschiotti; D Piccioni; E Bonmassar
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 8.  Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.

Authors:  Ornella Franzese; Francesco Torino; Maria Pia Fuggetta; Angelo Aquino; Mario Roselli; Enzo Bonmassar; Anna Giuliani; Stefania D'Atri
Journal:  Oncotarget       Date:  2017-06-20

9.  DTIC xenogenized lines obtained from an L1210 clone: clonal analysis of cytotoxic T lymphocyte reactivity.

Authors:  O Marelli; P Franco; G Canti; L Ricci; N Prandoni; A Nicolin; H Festenstein
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

10.  Antibody-dependent cellular cytotoxicity against drug-induced antigens in L5178Y mouse lymphoma.

Authors:  P Franco; F Veronese; F Levi; A Goldin; A Nicolin
Journal:  Br J Cancer       Date:  1982-08       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.